Because of its essential role in regulating adipogenesis and higher expression in the WAT, PPARγ has been a pharmacological target for drug development (Lehmann et al., 1995; Lefterova et al., 2014) in combating metabolic diseases such as insulin resistance and type 2 diabetes. This evidence concerns the gene PPARG and type 2 diabetes mellitus.